Exposed: 10 CENT Crypto to Explode April 20th?

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Sanat Chattopadhyay net worth and biography

Sanat Chattopadhyay Biography and Net Worth

Insider of Merck & Co., Inc.

Sanat Chattopadhyay is executive vice president and president, Merck Manufacturing Division. He has responsibility for the company’s worldwide manufacturing and supply operations across a global network of sites for pharmaceuticals, vaccines, biologics and animal health products.

A proven leader in the biopharmaceutical industry, Sanat joined Merck in November 2009 as senior vice president of global vaccines and sterile manufacturing operations, spearheading the transformation of manufacturing and supply chain to grow and globalize its vaccine business. Under Sanat’s leadership, Merck is currently executing significant expansion of its biologics and vaccines manufacturing capacity to reach more patients around the globe.

Before joining Merck, he served as senior vice president, technical operations and product supply, for Wyeth Pharmaceuticals, with responsibility for product supply, process development and operational excellence. Previously, he worked at Aventis and its predecessor companies as senior vice president, industrial operations, having served in many positions with increasing responsibilities for global supply chain, technology and manufacturing sites across North America, Europe and Asia Pacific.

A graduate chemical engineer from Jadavpur University and post-graduate industrial engineer from NITIE, India, Sanat is widely travelled, having lived with his family in five countries across three continents.

What is Sanat Chattopadhyay's net worth?: The estimated net worth of Sanat Chattopadhyay is at least $3.86 million as of January 9th, 2023. Mr. Chattopadhyay owns 29,500 shares of Merck & Co., Inc. stock worth more than $3,855,945 as of April 26th. This net worth estimate does not reflect any other assets that Mr. Chattopadhyay may own. Learn More about Sanat Chattopadhyay's net worth.
How do I contact Sanat Chattopadhyay?: The corporate mailing address for Mr. Chattopadhyay and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Sanat Chattopadhyay's contact information.
Has Sanat Chattopadhyay been buying or selling shares of Merck & Co., Inc.?: Sanat Chattopadhyay has not been actively trading shares of Merck & Co., Inc. in the last ninety days. Most recently, Sanat Chattopadhyay sold 134,055 shares of the business's stock in a transaction on Thursday, April 13th. The shares were sold at an average price of $115.07, for a transaction totalling $15,425,708.85. Learn More on Sanat Chattopadhyay's trading history.
Who are Merck & Co., Inc.'s active insiders?: Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.
Are insiders buying or selling shares of Merck & Co., Inc.?: During the last year, Merck & Co., Inc. insiders bought shares 1 times. They purchased a total of 3 shares worth more than $341.04. During the last year, insiders at the sold shares 11 times. They sold a total of 460,551 shares worth more than $53,354,373.87. The most recent insider tranaction occured on February, 13th when insider Joseph Romanelli sold 1,000 shares worth more than $124,890.00. Insiders at Merck & Co., Inc. own 0.1% of the company. Learn More about insider trades at Merck & Co., Inc..
Information on this page was last updated on 2/13/2024.

Sanat Chattopadhyay Insider Trading History at Merck & Co., Inc.

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/13/2023	Sell	134,055	$115.07	$15,425,708.85
1/9/2023	Sell	83,994	$112.29	$9,431,686.26	29,500
10/28/2022	Sell	100,292	$100.10	$10,039,229.20	45,608
10/29/2021	Sell	24,619	$87.32	$2,149,731.08
8/13/2020	Sell	10,380	$83.01	$861,643.80
2/12/2019	Sell	73,727	$78.62	$5,796,416.74	95,343
8/3/2018	Sell	29,208	$65.20	$1,904,361.60	70,675

Sanat Chattopadhyay Buying and Selling Activity at Merck & Co., Inc.

Merck & Co., Inc. Company Overview

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Today's Range

Now: $130.71

$128.76

$132.80

50 Day Range

MA: $126.34

$120.54

$131.95

2 Week Range

Now: $130.71

$99.14

$133.10

Volume

12,747,423 shs

Average Volume

6,384,497 shs

Market Capitalization

$331.09 billion

P/E Ratio

933.64

Dividend Yield

2.43%

Beta

0.38

It’s now possible to know the win rate of every trade… BEFORE you take it!

From WealthPress | Ad

Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.

>> You can grab your FREE, laminated copies right here <<